A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated with an Advagraf or Prograf Based Immunosuppressive Regimen, Including a Long-Term Follow-Up

Trial Profile

A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated with an Advagraf or Prograf Based Immunosuppressive Regimen, Including a Long-Term Follow-Up

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Transplant rejection
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 19 Jul 2017 Planned End Date changed from 1 Nov 2025 to 1 May 2026.
    • 19 Jul 2017 Planned primary completion date changed from 1 Nov 2025 to 1 May 2026.
    • 06 Jul 2017 This trial has been completed in France according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top